Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Onconetix Inc ONCO

Healthcare Biotechnology
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix... see more

Recent & Breaking News (NDAQ:ONCO)

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

GlobeNewswire February 13, 2024

Onconetix(TM) Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

GlobeNewswire December 19, 2023

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix(TM)

GlobeNewswire December 18, 2023

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

GlobeNewswire November 2, 2023

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

GlobeNewswire November 1, 2023

Blue Water Biotech Issues Letter to Shareholders

GlobeNewswire October 30, 2023

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

GlobeNewswire October 10, 2023

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

GlobeNewswire August 28, 2023

Blue Water Biotech and Copay Consultants Collaborate to Build Copay Assistance Programs for Blue Water's Commercial Products

GlobeNewswire August 10, 2023

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

GlobeNewswire August 3, 2023

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

GlobeNewswire August 1, 2023

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

GlobeNewswire July 31, 2023

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

GlobeNewswire July 25, 2023

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

GlobeNewswire July 17, 2023

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

GlobeNewswire July 11, 2023

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

GlobeNewswire July 6, 2023

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

GlobeNewswire July 6, 2023

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

GlobeNewswire June 28, 2023

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

GlobeNewswire June 21, 2023

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

GlobeNewswire June 14, 2023